- Trials with a EudraCT protocol (179)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
179 result(s) found for: covid-19 AND vaccine.
Displaying page 1 of 9.
EudraCT Number: 2021-004016-26 | Sponsor Protocol Number: Clin_COVID-19_Corok | Start Date*: 2021-10-18 |
Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital | ||
Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection" | ||
Medical condition: None | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001993-52 | Sponsor Protocol Number: IMCOVAS | Start Date*: 2021-05-20 |
Sponsor Name:University of Antwerp | ||
Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc... | ||
Medical condition: Coronavirus disease-19 (COVID-19) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004788-29 | Sponsor Protocol Number: Covid_vacc_THL2021 | Start Date*: 2021-12-23 | |||||||||||
Sponsor Name:Finnish Institute for Health and Welfare | |||||||||||||
Full Title: COVID-19 vaccine immunological studies in Finland | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003547-24 | Sponsor Protocol Number: 21CH134 | Start Date*: 2021-08-25 | |||||||||||
Sponsor Name:CHU de Saint Etienne | |||||||||||||
Full Title: Factors influencing the COVID-19 vaccine immune response (reactogenicity and immunogenicity) according to age and presence or not of a past history of COVID-19. COVIMMUNAGE study | |||||||||||||
Medical condition: Volunteer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001590-31 | Sponsor Protocol Number: 22/01611 | Start Date*: 2022-10-20 |
Sponsor Name:Norwegian Institute of Public Health | ||
Full Title: A parallel group, prevention, phase iv, unblinded 2-arm study to investigate hospital admission and deaths due to COVID-19, after receiving an invitation to take a second booster COVID-19 vaccine c... | ||
Medical condition: COVID-19. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000454-26 | Sponsor Protocol Number: 76702 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Establishing the safety, tolerability and immunogenicity of intradermal delivery of mRNA SARS-CoV-2 vaccine in healthy adults | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001357-31 | Sponsor Protocol Number: IIV-478 | Start Date*: 2021-05-03 |
Sponsor Name:National Institute of Health and the Environment | ||
Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects | ||
Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004891-33 | Sponsor Protocol Number: T33/2021 | Start Date*: 2022-04-13 |
Sponsor Name:Turku University Hospital | ||
Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000880-63 | Sponsor Protocol Number: na | Start Date*: 2021-03-11 |
Sponsor Name:Skåne University Hospital, department of rheumatology in Lud and Malmö | ||
Full Title: COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA) | ||
Medical condition: rheumatoid arthritis, SLE, systemic vasculitis, systemic sclerosis, spondylarthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002327-38 | Sponsor Protocol Number: NL77670.029.21 | Start Date*: 2021-05-26 | ||||||||||||||||
Sponsor Name:Academic Medical Center | ||||||||||||||||||
Full Title: PREGCOVAC-19: the follow up of pregnant women who received COVID-19 vaccination in the Dutch national vaccination program | ||||||||||||||||||
Medical condition: Pregnant women aged ≥ 18 years who are scheduled for COVID-19 vaccination within the Dutch national vaccination program with any of the currently or future available vaccines that are used for preg... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000930-32 | Sponsor Protocol Number: SJ2021005 | Start Date*: 2021-04-27 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 | ||
Medical condition: hemodialysis patients hemodialysis patients with comorbidities | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006003-42 | Sponsor Protocol Number: ENFORCE | Start Date*: 2020-12-30 | |||||||||||
Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen | |||||||||||||
Full Title: National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE) | |||||||||||||
Medical condition: The aim is to study primarily effectiveness as well as safety of citizens being vaccinated with one of the SARS-CoV2 vaccines being applied in the Danish COVID-19 vaccine programme. Whereas ongoi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001459-15 | Sponsor Protocol Number: HS-2021-02 | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study | ||
Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001103-32 | Sponsor Protocol Number: HEPCOViVac | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: The HEPCOViVac Registry - Immunological response in patients with liver disease vaccinated against COVID-19 | ||
Medical condition: Cirrhotic chronic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000182-33 | Sponsor Protocol Number: 76421 | Start Date*: 2021-03-25 |
Sponsor Name:Radboudumc | ||
Full Title: Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers | ||
Medical condition: Immunogenicity of the mRNA BNT162b2 COVID-19 vaccine. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003331-28 | Sponsor Protocol Number: LONGCOV-VAC | Start Date*: 2021-07-29 |
Sponsor Name:Felix Gutierrez Rodero | ||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the COMIRNATY vaccine (COVID-19 mRNA vaccine, Pfizer-BioNTech) in people with long COVID | ||
Medical condition: Unlike what happens with other respiratory viruses, in a significant proportion of patients who have suffered from the disease, general and multi-organ symptoms may persist for months, which has be... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000683-30 | Sponsor Protocol Number: CoVacc | Start Date*: 2021-03-03 |
Sponsor Name:Umeå university | ||
Full Title: CoVacc - Immune response to vaccination against Covid-19, an open multicenter phase IV study | ||
Medical condition: Individuals with and without pre-existing immunity to Covid-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004608-17 | Sponsor Protocol Number: SJ2021100 | Start Date*: 2021-10-18 |
Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
Full Title: Effectivity of a mRNA-1273 booster vaccine against Covid-19 breakthrough infections in hemodialysis patients: a multicenter interventional study | ||
Medical condition: hemodialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002014-14 | Sponsor Protocol Number: COV-PBO-MO28 | Start Date*: 2021-04-20 |
Sponsor Name:Fakultní nemocnice Hradec Králové | ||
Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w... | ||
Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002984-23 | Sponsor Protocol Number: 33-391ex20/21 | Start Date*: 2021-08-01 |
Sponsor Name:Medical University of Graz | ||
Full Title: Retrospective quantification of anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in patients treated with peritoneal dialysis | ||
Medical condition: Chronic peritoneal dialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.